Literature DB >> 11081900

Current indications for left thoracotomy in coronary revascularization and valvular procedures.

J W Pratt1, T E Williams, R E Michler, D A Brown.   

Abstract

BACKGROUND: Left thoracotomy is infrequently used for cardiac procedures, but its application in reoperative and minimally invasive coronary revascularization and in valvular procedures has been reported recently.
METHODS: Three case reports and a review of the current literature illustrate the unique benefits of this approach for myocardial revascularization and valve replacement.
RESULTS: Reoperative coronary revascularization of the left anterior descending and circumflex coronary arteries was performed off-pump via a left posterolateral thoracotomy. For the second case, this approach was used for coronary artery bypass grafting of the right coronary and left anterior descending arteries with femoral-femoral cardiopulmonary bypass in a patient with congestive heart failure and coronary artery disease who also required closure of a patent ductus arteriosus. In the third case, mitral valve replacement using femoral venous and aortic cannulation for cardiopulmonary bypass was performed via a left thoracotomy to avoid a retrosternal gastric conduit in a patient with severe mitral stenosis and congestive heart failure. All patients returned to normal activity and are asymptomatic.
CONCLUSIONS: These case reports and a comprehensive review of the literature demonstrate the utility of left thoracotomy as an alternative approach to standard median sternotomy in selected cases of revascularization and valvular procedures.

Entities:  

Mesh:

Year:  2000        PMID: 11081900     DOI: 10.1016/s0003-4975(00)01937-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  1 in total

1.  Redo off-pump coronary artery bypass grafting via a left thoracotomy.

Authors:  I Duvan; S Ates; B E Onuk; U P Sungar; M Kurtoglu; Y H Karagoz
Journal:  Cardiovasc J Afr       Date:  2014-12-02       Impact factor: 1.167

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.